Lexicon Pharmaceuticals Inc.
LXRX | NASDAQ
$2.04
-$0.01 (-0.49%)
At close: Sep 21, 2026, 4:00 PM ET
$2
-$0.04 (-1.85%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Market Data
Market Cap $910.6M
Enterprise Value $715.55M
Beta 1.03
Average Volume 3.19M
Shares Outstanding (Diluted) 437.65M
Shares Change YoY 20.38%
Institutional Ownership 80.80%
Exchange NASDAQ
ISIN US5288723027
Price Performance
Price Change 1M -12.4%
Price Change 3M -5.6%
Price Change 6M 21.4%
Price Change YTD 79.0%
Price Change 1Y 75.9%
Price Change 3Y 90.7%
Price Change 5Y -58.7%
1M CAGR (ann.) -13.1%
1Y CAGR (ann.) 88.1%
5Y CAGR (ann.) -15.2%
All-Time CAGR -12.1%
Valuation
PE Ratio -13.60
Forward PE N/A
PEG Ratio 0.11
Forward PEG -0.58
PS Ratio 21.85
Forward PS 45.50
PB Ratio 5.19
P/FCF Ratio -11.37
P/Adj. FCF Ratio -9.49
P/OCF Ratio -11.33
EV/Sales 17.26
EV/EBIT -13.57
EV/EBITDA -13.69
EV/FCF -8.98
Earnings Yield -7.3%
FCF Yield -8.8%
Adj. FCF Yield -10.5%
Financial Health
Net Cash $190.61M
Total Debt $0
Cash & Short-Term Investments $190.61M
Total Assets $250.06M
Current Ratio 13.37
Quick Ratio 13.29
Debt / Equity Ratio 0.34
Debt / EBITDA -0.00
Debt / FCF -0.00
OCF / Debt N/A
Interest Coverage -6.50
Altman Z-Score -3.90
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 98.8%
Operating Profit Margin -131.4%
EBITDA Margin -126.0%
Net Profit Margin -147.4%
FCF Margin -192.2%
Adj. FCF Margin -230.3%
SBC / Revenue 38.0%
SBC Impact (per share) -19.8%
Returns
Return on Assets -24.4%
Return on Equity -40.4%
Return on Invested Capital -23.0%
Return on Capital Employed -23.2%
Return on Tangible Assets -29.7%
Historical Growth (CAGR)
Revenue CAGR 3Y 366.7%
Revenue CAGR 5Y 42.4%
Revenue CAGR 10Y -12.7%
EPS CAGR 3Y 75.0%
EPS CAGR 5Y 26.4%
EPS CAGR 10Y 15.4%
FCF CAGR 3Y 46.1%
FCF CAGR 5Y 2.3%
FCF CAGR 10Y 2.7%
Analyst Forecasts
Analyst Rating Hold
Analyst Count 14
EPS Growth Next 3Y 24.4%
Revenue Growth Next 3Y 33.7%
Earnings Date Nov 4, 2026
EPS Estimate (next Q) -$0.06
EPS Growth Est (next Q) 50.0%
Revenue Est (next Q) $2.83M
Revenue Growth Est (next Q) -80.0%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $6
Price Target Upside 194.1%
Cash Flow
Operating Cash Flow $-79.72M
Free Cash Flow $-79.72M
Adj. Free Cash Flow $-95.49M
FCF Per Share -$0.18
OCF Per Share -$0.18
OCF/S Ratio -192.2%
Income Statement
Revenue $41.47M
Gross Profit $40.99M
Operating Income $-54.5M
EBITDA $-52.25M
Net Income $-61.12M
EPS (Diluted) -$0.15
Revenue / Employee $511.96K
Profit / Employee $-754.53K
Employees 81
Add to Watchlist
Select watchlists to add or remove LXRX